JPRN-jRCT2080224749已完成1 期
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Amgen K.K.
- 入组人数
- 175
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1. Age >= 18 years old
- •2. (Multiple myeloma [MM] participants) Pathologically documented, multiple myeloma relapsed or refractory disease after at least 2 lines of therapy
- •3. (MM participants only) Measurable disease per the International Myeloma Working Group response criteria
- •4. (Acute myeloid leukemia [AML] participants) AML as defined by the World Health Organization Classification persisting or recurring following one or more treatment courses; and for participants in Japan, determined by the investigator to be not eligible for approved anticancer drug therapy in Japan; EXCEPT acute promyelocytic leukemia.
- •5. (AML participants only) More than 5% blasts in bone marrow and Circulating white blood cells < 25,000/ul.
- •6. Must be willing and able to undergo a core bone marrow biopsy (MM participants only) and bone marrow aspirate (MM and AML participants) at screening.
- •7. Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.
- •8. (MM participants only) Satisfactory hematological function without transfusion or growth factor support
- •9. Life expectancy of > 3 months, in the opinion of the investigator
- •10. Adequate hepatic function
- •11. Adequate cardiac function
- •12. Adequate renal function
- •13. Female participants of childbearing potential must have a negative serum or urine pregnancy test
- •Other Inclusion Criteria May Apply.
排除标准
- •1. Previously received an allogeneic stem cell transplant within 6 months OR having received immunosuppressive therapy within the last three months OR having signs or symptoms of acute or chronic graft-versus-host disease
- •2. Autologous stem cell transplant less than 90 days prior to study day 1
- •3. (MM participants only) MM with Immunoglobulin M subtype
- •4. (MM participants only) Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes syndrome
- •5. (MM participants only) Existing plasma cell leukemia
- •6. (MM participants only) Waldenstrom's macroglobulinemia
- •7. (MM participants only) Amyloidosis
- •8. Infection requiring intravenous anti-infective treatments within 1 week of study enrollment (day 1)
- •9. Myocardial infarction within 6 months of enrollment, symptomatic congestive heart failure (New York Heart Association > class II)
- •10. History of arterial thrombosis (eg, stroke or transient ischemic attack) in the past 6 Months prior to enrollment
- •11. Currently receiving treatment in another investigational device or drug study. Other investigational procedures while participating in this study will be allowed if approved by Amgen medical monitor
- •12. Participants with elevated cardiac troponin above the manufacturer's 99th percentile upper reference limit for ADVIA Centaur XP assay at screening performed by the central laboratory
- •13. Participants with evidence of recent cardiac injury at screening based on creatine kinase-muscle/brain, N-terminal prohormone of brain natriuretic peptide, and electrocardiogram
- •Other exclusion Criteria May Apply.
- •14. (AML Part 3d only) History of QT prolongation, torsades de pointes, ventricular tachycardia and cardiac arrest
- •15. History or evidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection unless agreed upon with medical monitor.
研究者
相似试验
暂停
1 期
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia (AML)JPRN-jRCT2031210152ocal Contact200
暂停
1 期
A Phase 1 Study of AMG 330 in Subjects With Myeloid MalignanciesRelapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic SyndromeJPRN-jRCT2071210044Contact Local256
已完成
不适用
A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myelomasolide tumorentumor in the organsNL-OMON44939Amgen42
已完成
不适用
A first-in-human study to evaluate the safety and performance of placebo excipient-coated high-density microarray patches applied by an integrated application device.VaccinationsPublic Health - Other public healthACTRN12620000179932Vaxxas Pty Ltd43
招募中
1 期
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell MalignanciesHematologic CancerJPRN-jRCT2031230249Satomi Natsuko128